This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Harris, S. T. Articles by Chines, A. A. Search for Related Content PubMed PubMed Citation Articles by Harris, S. T. Articles by Chines, A. A.

Effect of Combined Risedronate and Hormone Replacement Therapies on Bone Mineral Density in Postmenopausal Women¹

University of California (S.T.H.), San Francisco, California 94117; University of Aarhus (E.F.E.), Aarhus, DK-8000 Denmark; Chicago Center for Clinical Research (M.D.), Chicago, Illinois 60610; Clinical Research Center of South Florida (M.P.E.), Stuart, Florida 34996, and (A.H.M.) Leesburg, Florida 34748; Jerry L. Pettis Veteran’s Affairs Medical Center (D.J.B.), Loma Linda, California 92357; and Procter & Gamble Pharmaceuticals (C.E.C., A.A.C.), Cincinnati, Ohio 45040

Address all correspondence and requests for reprints to: Dr. Steven T. Harris, University of California Osteoporosis Programs, 350 Parnassus Avenue, Suite 706, San Francisco, California 94117-3608.

Both hormone replacement therapy (HRT) and bisphosphonates are efficacious in the prevention and treatment of postmenopausal osteoporosis. Combined therapy with bisphosphonate and HRT is likely to be used in clinical practice, and limited data are available regarding its efficacy and safety.

This was a 1-yr, double blind, placebo-controlled study in which 524 postmenopausal women received daily treatment with conjugated equine estrogens (0.625 mg) alone or in combination with risedronate (5 mg). Women who had not undergone hysterectomy received medroxyprogesterone acetate (up to 5 mg, daily or cyclically) at the discretion of the investigator. The primary efficacy end point was the percent change from baseline in mean lumbar spine bone mineral density (BMD) at 1 yr. Changes in BMD at the proximal femur and forearm, bone turnover markers, and histology and histomorphometry were also assessed.

At 12 months, significant (P < 0.05) increases from baseline in lumbar spine BMD were observed in both treatment groups (HRT-only, 4.6%; combined risedronate-HRT, 5.2%); the difference between the two groups was not statistically significant. Both therapies led to significant increases in BMD at 12 months at the femoral neck (1.8% and 2.7%, respectively), femoral trochanter (3.2% and 3.7%), distal radius (1.7% and 1.6%), and midshaft radius (0.4% and 0.7%). The differences between groups were statistically significant (P < 0.05) at the femoral neck and midshaft radius. Both combined risedronate-HRT and HRT-only produced significant decreases in the biochemical markers of bone turnover, with somewhat greater decreases in the combined treatment group. Bone biopsy data showed normal bone structure and normal mineralization with either treatment. Expected decreases in bone turnover were observed and were greater in the combined treatment group (68–79% reduction relative to baseline values, P < 0.005). Overall, combined treatment had a safety profile similar to that of HRT-only, including bone and gastrointestinal safety profiles.

In conclusion, the combined treatment with risedronate and HRT had a favorable effect on BMD similar to that of HRT alone at the lumbar spine and slightly, but significantly, greater than that of HRT alone at the femoral neck and midshaft radius. The combined treatment was well tolerated, and there were no adverse effects on the skeleton.

This article has been cited by other articles:

				E. J. MacLaughlin and C. L. Raehl ASHP Therapeutic Position Statement on the Prevention and Treatment of Osteoporosis in Adults Am. J. Health Syst. Pharm., February 15, 2008; 65(4): 343 - 357. [Full Text] [PDF]

				J. M. K. Cheong, B. R. Martin, G. S. Jackson, D. Elmore, G. P. McCabe, J. R. Nolan, S. Barnes, M. Peacock, and C. M. Weaver Soy Isoflavones Do Not Affect Bone Resorption in Postmenopausal Women: A Dose-Response Study Using a Novel Approach with 41Ca J. Clin. Endocrinol. Metab., February 1, 2007; 92(2): 577 - 582. [Abstract] [Full Text] [PDF]

				C. I. Rohr, J. M. Clements, and A. Sarkar Treatment and prevention practices in postmenopausal women after bone mineral density screening at a community-based osteoporosis project. J Am Osteopath Assoc, July 1, 2006; 106(7): 396 - 401. [Abstract] [Full Text] [PDF]

				L. I. Plotkin, J. I. Aguirre, S. Kousteni, S. C. Manolagas, and T. Bellido Bisphosphonates and Estrogens Inhibit Osteocyte Apoptosis via Distinct Molecular Mechanisms Downstream of Extracellular Signal-regulated Kinase Activation J. Biol. Chem., February 25, 2005; 280(8): 7317 - 7325. [Abstract] [Full Text] [PDF]

				Osteoporosis Obstet. Gynecol., October 1, 2004; 104(4_suppl): 66S - 76S. [Full Text] [PDF]

				S. Evio, A. Tiitinen, K. Laitinen, O. Ylikorkala, and M. J. Valimaki Effects of Alendronate and Hormone Replacement Therapy, Alone and in Combination, on Bone Mass and Markers of Bone Turnover in Elderly Women with Osteoporosis J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 626 - 631. [Abstract] [Full Text] [PDF]

				S. A. Brown and J. L. Sharpless Osteoporosis: An Under-appreciated Complication of Diabetes Clin. Diabetes, January 1, 2004; 22(1): 10 - 20. [Abstract] [Full Text] [PDF]

				M. P. Ettinger Aging Bone and Osteoporosis: Strategies for Preventing Fractures in the Elderly Arch Intern Med, October 13, 2003; 163(18): 2237 - 2246. [Abstract] [Full Text] [PDF]

				T. E. R. Brown Osteoporosis: A Pharmacotherapy Update Journal of Pharmacy Practice, June 1, 2003; 16(3): 164 - 169. [Abstract] [PDF]

				B. Ettinger and J. P. Bilezikian For Osteoporosis, Are Two Antiresorptive Drugs Better Than One? J. Clin. Endocrinol. Metab., March 1, 2002; 87(3): 983 - 984. [Full Text] [PDF]

				O. Johnell, W. H. Scheele, Y. Lu, J.-Y. Reginster, A. G. Need, and E. Seeman Additive Effects of Raloxifene and Alendronate on Bone Density and Biochemical Markers of Bone Remodeling in Postmenopausal Women with Osteoporosis J. Clin. Endocrinol. Metab., March 1, 2002; 87(3): 985 - 992. [Abstract] [Full Text] [PDF]

				Bisphosphonates for osteoporosis DTB, September 1, 2001; 39(9): 68 - 72. [Abstract] [Full Text] [PDF]

				Risedronate Plus Hormone Therapy for Postmenopausal Women Journal Watch Women's Health, July 3, 2001; 2001(703): 9 - 9. [Full Text]

				Risedronate Plus Hormone Replacement for Postmenopausal Women Journal Watch (General), June 5, 2001; 2001(605): 6 - 6. [Full Text]

				R. R. Recker and R. P. Heaney The Role of Combination Treatment for Osteoporosis J. Clin. Endocrinol. Metab., May 1, 2001; 86(5): 1888 - 1889. [Full Text]